Organisation paid for research Program year 2024 Source: CMS Open Payments

Victory Clinical Research

Neither a doctor nor a teaching hospital

Research payments

$180,275

38 payments

Through program year 2024, Victory Clinical Research is reported as receiving $180,275 in research payments, across 38 payments.

By program year

4 rows
Year Kind Amount Payments
2024 Research $454 1
2021 Research $17,639 10
2020 Research $39,212 14
2019 Research $122,970 13

Breakdown

Who paid Research payments · program years 2019–2024
  1. Allergan Inc. $147,412 18 payments
  2. AMAG Pharmaceuticals, Inc. $15,643 9 payments
  3. Sanofi Pasteur Inc. $10,540 9 payments
  4. AbbVie, Inc. $6,680 2 payments
Studies the money was for Research payments · program years 2019–2024
  1. AURORA A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis $79,713 2 payments
  2. AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis $27,275 7 payments
  3. A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects With Nonalcoholic Steatohepatitis. $24,586 2 payments
  4. AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis $15,839 7 payments
  5. A Phase 3, Randomized, Open-Label Multicenter Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Ferumoxytol for the Treatment of Iron Deficiency Anemia Ida in Pediatric Subjects $11,441 4 payments
  6. Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly with Routine Pediatric Vaccines in Healthy Infants and Toddlers $10,540 9 payments
  7. P11-282 $6,680 2 payments
  8. A Phase 3, Randomized, Open-Label Multicenter Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Ferumoxytol for the Treatment of Iron Deficiency Anemia (Ida) in Pediatric Subjects $2,902 3 payments
  9. A Phase 3, Randomized, Open-Label Multicenter Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Ferumoxytol for the Treatment of Iron Deficiency Anemia (Ida) in Pediatric Subjects $1,300 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2024

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record